MABVAX THERAPEUTICS HLDGS INC
MBVX
MBVX was delisted on the 10th of July, 2018.
15 hedge funds and large institutions have $1.72M invested in MABVAX THERAPEUTICS HLDGS INC in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
1,348% more capital invested
Capital invested by funds: $119K → $1.72M (+$1.6M)
50% more funds holding
Funds holding: 10 → 15 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$1.82M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$18.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$7.32K |
| 5 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
+$728 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $1.62M | +$1.82M | +831,734 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $20K | +$18.6K | +8,493 | +495% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $20K | +$22.5K | +10,266 | New |
|
|
BCM
4
Biomark Capital Management
Greenwich,
Connecticut
| $17K | – | – | – |
|
5
Bank of America
Charlotte,
North Carolina
| $12K | – | – | – |
|
|
BW
6
Bison Wealth
Atlanta,
Georgia
| $10K | – | – | – |
|
|
BJL
7
Brighton Jones LLC
Seattle,
Washington
| $7K | – | – | – |
|
|
DRD
8
Dennis R. Delaney
| $7K | – | – | – |
|
|
TSS
9
Two Sigma Securities
New York
| $7K | +$7.32K | +3,348 | New |
|
|
BCI
10
Brinker Capital Investments
Berwyn,
Pennsylvania
| $1K | +$728 | +333 | New |
|
11
Morgan Stanley
New York
| – | +$273 | +125 | New |
|
MBVX Hedge Fund Activity: Q3 2017 in Review
15 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in MABVAX THERAPEUTICS HLDGS INC (MBVX) for Q3 2017, worth a combined $1.72M — up 1,348% from $119K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MBVX positions and 0 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $1.82M.
- 15 institutional investors held MABVAX THERAPEUTICS HLDGS INC (MBVX) as of Q3 2017, up from 10 in Q2 2017.
- Funds reported $1.72M of MABVAX THERAPEUTICS HLDGS INC stock for Q3 2017, up 1,348% quarter-over-quarter.
- 5 funds opened new MABVAX THERAPEUTICS HLDGS INC positions in Q3 2017 and 0 closed out, a net change of +5 holders.
- The largest MABVAX THERAPEUTICS HLDGS INC buyer in Q3 2017 was Cambridge Investment Research Advisors, an estimated $1.82M added.
Based on aggregated 13F filings for Q3 2017.